Yunsoo Kim

Array ( [id] => 18256359 [patent_doc_number] => 20230083398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => Immunoglobulin Preparation and Storage System for an Immunoglobulin Preparation [patent_app_type] => utility [patent_app_number] => 17/864622 [patent_app_country] => US [patent_app_date] => 2022-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420164 [patent_doc_number] => 20230174625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => METHOD FOR PURIFYING IMMUNOGLOBULIN SOLUTIONS [patent_app_type] => utility [patent_app_number] => 17/863587 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581642 [patent_doc_number] => 20230263895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/808029 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960094 [patent_doc_number] => 20220340674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT [patent_app_type] => utility [patent_app_number] => 17/807211 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17807211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387754 [patent_doc_number] => 20240277624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS [patent_app_type] => utility [patent_app_number] => 18/568363 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20241015 [patent_doc_number] => 12421324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Methods and formulations for reducing reconstitution time of lyophilized polypeptides [patent_app_type] => utility [patent_app_number] => 17/832463 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 11239 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18226878 [patent_doc_number] => 20230065872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING [patent_app_type] => utility [patent_app_number] => 17/831645 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18297048 [patent_doc_number] => 20230106734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/738131 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805928 [patent_doc_number] => 20220257763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ROOM TEMPERATURE STABLE LYOPHILIZED PROTEIN [patent_app_type] => utility [patent_app_number] => 17/738870 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805919 [patent_doc_number] => 20220257754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/731718 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20301157 [patent_doc_number] => 12447127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Thermostable vaccine compositions and methods of preparing the same [patent_app_type] => utility [patent_app_number] => 17/732224 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 8854 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850599 [patent_doc_number] => 20220280640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/731671 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18181526 [patent_doc_number] => 20230042255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) [patent_app_type] => utility [patent_app_number] => 17/726741 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25507 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17726741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248743 [patent_doc_number] => 20240199730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => AN ANTI-TSLP FAB WITH IMPROVED STABILITY [patent_app_type] => utility [patent_app_number] => 18/287240 [patent_app_country] => US [patent_app_date] => 2022-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274639 [patent_doc_number] => 11613570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Method of treating dupuytren's disease using a pre-filled syringe [patent_app_type] => utility [patent_app_number] => 17/721106 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 10880 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17721106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586674 [patent_doc_number] => 20240384231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => MATERIALS AND METHODS FOR ENHANCED STEM-CELL LIKE MEMORY T CELL ENGINEERING [patent_app_type] => utility [patent_app_number] => 18/554240 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233808 [patent_doc_number] => 20240191000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => HIGH CONCENTRATION ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/553228 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20219955 [patent_doc_number] => 20250282886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => GLYCAN-MEDIATED PROTEIN DEGRADATION [patent_app_type] => utility [patent_app_number] => 18/283731 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702939 [patent_doc_number] => 20220202945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG [patent_app_type] => utility [patent_app_number] => 17/699868 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11474 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232252 [patent_doc_number] => 20240189443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR [patent_app_type] => utility [patent_app_number] => 18/550346 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550346 [rel_patent_id] =>[rel_patent_doc_number] =>)